GUSHENGTANG HOLDINGS LIMITED (02273)

Equity Research Report　|　Industry: Private TCM Medical Services Chain　|　Report Date: September 13, 2026　|　Data as of the Hong Kong market close on September 11, 2026; September 13, 2026 was a Sunday, and there was no new Hong Kong market closing data. Reporting currency: Hong Kong dollars (HKD).

This report was automatically compiled by AI based on publicly available information and is for reference only. It does not constitute investment advice.

1. Key Summary

Gushengtang (02273.HK) most recently disclosed first-half 2026 revenue of RMB 1.653 billion, up 10.57% year on year; profit attributable to owners of the parent was approximately RMB 221 million, up 45.54% year on year. Profit growth was significantly faster than revenue growth, indicating improved operating leverage and profitability. The company also declared an interim dividend of HKD 1.15 per share. The business remains highly concentrated in healthcare solutions, which accounted for approximately 98.9% of revenue in 2024; offline medical institutions are the primary source of revenue.

The company focuses on private TCM medical services chains. In 2024, it operated a total of 79 medical institutions in mainland China and Singapore, with approximately 5.411 million patient visits and a repeat-visit rate of approximately 67.1%. The main growth drivers are offline store expansion, M&A integration, the physician-resource network, online bookings and follow-up consultations, chronic disease management, and the OMO model. In the first half of 2026, healthcare solutions revenue increased by approximately 10.8% year on year, mainly driven by the expansion of offline medical institutions. The company also plans to acquire 100% of three TCM medical institutions in Malaysia. As of September 13, 2026, however, completion of the transaction had not been confirmed, and the consideration and historical operating data of the target companies had not been disclosed.

In terms of earnings quality, overall gross margin was approximately 30.1% in 2024. Physician costs and materials costs accounted for approximately 80.2% of cost of sales, indicating that the company is relatively sensitive to physician resources, consultation-fee sharing, and the cost of Chinese medicinal materials. Net trade receivables were RMB 269.4 million in 2024 and inventories were RMB 179.5 million. Medical-insurance settlement periods may extend to 365 days from the transaction date, meaning business expansion will involve a certain level of working-capital usage. Institutions generally still expect revenue and earnings to grow from 2026 to 2028, but these forecasts are research-house models, and some predate the latest interim results; they should not be regarded as formal company guidance.

As of September 11, 2026, the share price closed at HKD 26.54, below the MA5, MA10, and MA20. RSI was approximately 45.64. The technical picture indicated weak consolidation but had not entered the traditional extreme-oversold zone. After the interim-results catalyst, the share price fell from approximately HKD 29.10 and recently fluctuated around HKD 26–27. Trading volume was approximately 600,000 shares, below the three-month average of approximately 970,000 shares, with no clear high-volume sell-off or confirmed reversal. Market-capitalization and P/E data differ across platforms and earnings definitions; the current dynamic P/E is approximately 12.1x–13.4x.

2. Company Overview

2.1 Basic Information

2.2 Main Businesses and Product Mix

• Healthcare solutions: Including TCM consultations and diagnoses, prescription services, Chinese-medicine decoction and medication, acupuncture, tuina, moxibustion, cupping and other physical therapies, certain nursing treatments, chronic disease management, online follow-up consultations, online consultations, and bookings for offline treatment. Revenue was RMB 2.987656 billion in 2024, accounting for approximately 98.9% of full-year revenue, versus RMB 2.287100 billion in 2023, representing year-on-year growth of approximately 30.6%.
• Healthcare product sales: Mainly including premium medicinal materials, Chinese medicinal materials and related products, Ejiao, cordyceps, bird’s nest, dendrobium, American ginseng, nutritional products, and health products. Revenue was RMB 34.721 million in 2024, versus RMB 36.251 million in 2023, accounting for approximately 1.1% of full-year revenue; gross margin was approximately 36.0% in 2024.
• Offline medical institutions and offline pharmacies: Revenue was RMB 2.740487 billion in 2024, accounting for 90.7% of total revenue and increasing 34.5% year on year.
• Online healthcare platform: Providing bookings, online consultations, and follow-up consultations through the official website, mobile application, WeChat official account, WeChat mini-programs, and third-party online platforms. Revenue was RMB 281.890 million in 2024, accounting for 9.3% of total revenue and declining 1.5% year on year.
• Expansion model: The company uses parallel greenfield-development and M&A approaches. In 2024, it acquired or integrated Kunshan Laien Clinic, Singapore Baozhongtang, Beijing Asian Games Village TCM Hospital, Ningbo Guyuantang, and other medical institutions.
• Operating model: Offline medical institutions form the core, while online platforms support customer acquisition, follow-up consultations, and service extension, creating an online-offline integrated OMO model.

2.3 Position in the Industry Value Chain and Cost/Profit Structure

Gushengtang occupies a midstream-to-downstream position in the TCM medical-services value chain. Upstream, it connects with TCM physicians and renowned-doctor resources, Chinese herbal slices and premium medicinal materials, pharmaceutical and medical consumables, property, and online traffic services. Midstream, it provides diagnosis, prescriptions, decoction, acupuncture, tuina, moxibustion, and chronic disease management through offline medical institutions, internet hospitals, and digital systems. Downstream, it provides healthcare services and products to individual patients, medical-insurance payers, commercial-insurance customers, and corporate customers.

• Principal materials purchased and used include Chinese herbal slices and premium medicinal materials, Chinese-medicine decoction materials, pharmaceuticals and medical consumables, packaging materials, and consumables for tuina, acupuncture, and moxibustion. At the end of 2024, inventories of pharmaceuticals, consumables, and packaging materials were RMB 179.494 million, compared with RMB 152.950 million in 2023.
• Key upstream resources also include TCM physicians and renowned doctors, leased medical premises, third-party online traffic platforms, and healthcare-information and internet-hospital service providers. TCM diagnosis and treatment depend on physicians’ experience, professional reputation, and patient trust. Scarce renowned doctors have a substantial impact on revenue ceilings and the quality of store expansion.
• Cost of sales was RMB 2.113032 billion in 2024, of which physician and materials costs were RMB 1.694274 billion, or 80.2% of cost of sales; recurring operating expenses were RMB 418.758 million, or 19.8%. Physician and materials costs increased 29.3% year on year, while recurring operating expenses increased 33.8%.
• The company is not a complete price setter with respect to scarce renowned-doctor resources. It must attract and retain physicians through consultation-fee sharing, performance incentives, platform resources, and brand influence; ordinary physician resources can relatively readily be supplemented through recruitment and training.
• The company has some scale-based procurement advantages in pharmaceuticals and consumables, but Chinese medicinal materials, particularly premium materials, remain exposed to fluctuations in origin, variety, quality, and market prices. The research notes did not disclose major-supplier concentration or the share of the top five suppliers; supplier concentration therefore cannot be determined.
• Downstream customers include self-paying individual patients, patients settled through government medical insurance and social insurance, commercial-insurance customers, corporate customers, and patients referred through online platforms.
• The annual report shows that no single customer, or group of customers under common control, contributed 10% or more of company revenue. The research notes did not disclose the combined share of the top five customers, so traditional top-five customer concentration cannot be calculated. This data is based on the 2024 annual report and should be verified against the latest annual report.
• Revenue is more akin to a diversified mix of a large number of individual patients and medical-insurance settlement institutions, with no obvious risk of payment delays from a single large industrial or medical-device customer. Self-paying patients are sensitive to price, physician reputation, treatment results, and service experience. Medical-insurance settlement is affected by local policies, settlement periods, and compliance requirements.
• Patients may choose among public TCM hospitals, TCM departments of general hospitals, regional private TCM clinics, and other TCM chains. Public TCM hospitals have advantages in brand, specialists, medical insurance, research, and the treatment of complex diseases.
• Third-party online platforms may charge traffic and customer-acquisition commissions. In 2024, third-party customer-acquisition costs within selling and distribution expenses were RMB 7.080 million, or 1.9% of selling and distribution expenses, up 73.9% year on year, indicating that online traffic platforms are becoming increasingly important at the margin.
• As of December 31, 2024, net trade receivables were RMB 269.442 million, compared with RMB 179.927 million at the end of 2023, equivalent to approximately 8.9% of 2024 revenue of RMB 3.022377 billion. Inventories were RMB 179.494 million, and receivables plus inventories totaled approximately RMB 448.936 million. Individual patients generally settle in cash or through medical-insurance plans. Government medical-insurance settlements generally take 30–365 days from the transaction date, while corporate customers generally settle by bank transfer within 90 days of the transaction date. The data indicates relatively faster collections from self-paying patients, while medical-insurance business creates more noticeable receivables and working-capital usage. The research notes did not provide receivables turnover days or receivables as a percentage of net profit.
• The company did not disclose any single customer, or group of customers under common control, contributing more than 10% of revenue. The research notes also did not provide the combined share of the top five customers. Supplier concentration was likewise not disclosed. The available customer-concentration information only confirms that in 2024 no single customer or commonly controlled customer group accounted for 10% of revenue. The source is the 2024 annual report, which did not provide a top-five-customer definition; the latest annual report should prevail.

Gushengtang is neither an upstream resource company nor a pharmaceutical company centered on industrial Chinese-medicine production. Rather, it operates in the midstream-to-downstream medical-services segment driven by physician resources and patient traffic, with overall gross margin at approximately 30% since 2022. Profit improvement depends mainly on higher store density, improved physician-resource utilization, greater penetration of follow-up visits and memberships, productization of medical services, growth in in-hospital preparations, and better procurement and management efficiency, rather than simply on higher medicinal-material prices or manufacturing-style capacity expansion.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Results

The latest formal financial report is the interim results for the six months ended June 30, 2026, disclosed on August 28, 2026. Financial data are generally retained in the company’s disclosed currency, RMB; share prices, target prices, market capitalization, and dividends are in HKD. For 2025, the company also disclosed gross profit of RMB 1.01241 billion, EBITDA of RMB 621.9 million, profit for the year of RMB 352.069 million, basic EPS of RMB 1.49, and diluted EPS of RMB 1.45. For the first half of 2026, it additionally disclosed basic EPS of RMB 1.00, an interim dividend of HKD 1.15 per share, and EBITDA of approximately RMB 370 million.

Revenue increased by approximately 10% year on year in the first half of 2026, while profit attributable to owners of the parent rose 45.54%, meaning that profit growth significantly outpaced revenue growth. EBITDA increased by approximately 39.8%, indicating improved profitability and operating leverage. Healthcare-solutions revenue was RMB 1.645 billion, up approximately 10.8% year on year, mainly driven by offline medical institution expansion. Profit growth also exceeded revenue growth in 2025, but revenue growth slowed from the earlier high-growth phase. Future performance will depend on new-store expansion, M&A integration, overseas operations, and growth in consumer healthcare.

3.2 Earnings Forecasts

Institutional forecasts are research-house estimates rather than formal company guidance. CMB International’s August 2026 interim-results review listed 2026E–2028E revenue growth of approximately 14.5%, 16.9%, and 18.5%, respectively, and adjusted net-profit growth of approximately 14.7%, 17.6%, and 19.7%, respectively. However, the summary did not fully list the corresponding absolute revenue, net-profit, and EPS figures. The absolute figures for CMB International in the table come from an earlier April 2026 model and may not fully reflect the latest interim results or subsequent M&A developments. The forecast materials from BOCOM International, Guosen Securities, and Soochow Securities were published in April 2026. Adjusted net profit is not directly comparable with statutory net profit attributable to the parent.

3.3 Valuation and Institutional Ratings

The closing price on September 11, 2026 was HKD 26.82, down approximately 0.67% on the day; the 52-week price range was approximately HKD 24.32–34.20. Lixinger data as of September 10, 2026 showed a share price of HKD 27.00, total market capitalization of approximately HKD 6.328 billion, a trailing P/E of 13.14x, a P/B of 2.91x, a basic dividend yield of approximately 3.86%, and a dividend yield of approximately 6.81% including certain distributions. Lixinger also showed that the current P/E was below its historical 20th-percentile level of 17.89x and 50th-percentile level of 26.06x. Taking different platforms and earnings definitions together, the research notes suggest describing current valuation as follows: as of September 10–11, 2026, P/E was approximately 13x–16x and P/B approximately 2.9x. Differences mainly reflect TTM versus forecast earnings, statutory net profit attributable to the parent versus adjusted net profit, treatment of treasury shares and repurchases, the RMB/HKD exchange rate, and different data-update times. Based on the September 11 closing price of HKD 26.82, the potential upside to the Investing.com average target price of HKD 39.89 was approximately 48.7%; to the HKD 34.20 target price, approximately 27.5%; and to the HKD 45.50 target price, approximately 69.6%. These are static calculations and do not represent actual returns; they exclude dividends, foreign-exchange movements, target-price revisions, and the risk of earnings missing expectations. Institutional forecasts for 2026 net profit attributable to the parent were approximately RMB 420–430 million. Based on the current Hong Kong market-capitalization conversion method described in the notes, static forward P/E was approximately 13x–15x, although the precise result depends on exchange rates, share count, and forecast definitions.

4. Recent News and Announcements

4.1 Proposed Acquisition of 100% of Three Malaysian TCM Medical Institutions

On August 27, 2026, Gushengtang subsidiary Gushengtang Malaysia Sdn. Bhd. entered into sale and purchase agreements with the sellers to acquire 100% of YC TCM (Taman Segar) Sdn. Bhd., YC TCM Sdn. Bhd., and SWS Medical Sdn. Bhd., three Malaysian TCM medical institutions. The target companies mainly provide TCM consultation and treatment services. Following completion, their financial results will be consolidated into the group’s consolidated financial statements. The announcement did not disclose the specific consideration. Funding is intended to come from the net proceeds of a placing and the issuance of convertible bonds, together with the group’s idle funds. The sellers and ultimate beneficial owners of the target companies are independent third parties. The transaction does not constitute a connected transaction and, as all applicable percentage ratios are below 5%, it does not constitute a discloseable transaction under the Listing Rules. As of September 13, 2026, no completion announcement had been identified. The acquisition remains subject to the conditions precedent set out in the sale and purchase agreements and may or may not be completed.

4.2 Announcement of Interim Results and Interim Dividend for the Six Months Ended June 30, 2026

On August 28, 2026, Gushengtang announced its interim results for the six months ended June 30, 2026. Revenue was RMB 1.653 billion, up approximately 10.57% year on year; profit attributable to shareholders was approximately RMB 221 million, up approximately 45.54% year on year; basic EPS was approximately RMB 1.00; and healthcare-solutions revenue was RMB 1.645 billion, up approximately 10.8% year on year. The company also declared an interim dividend of HKD 1.15 per share. Revenue growth mainly came from healthcare solutions, driven by the expansion of offline medical institutions. Public reports show a minor rounding difference in profit attributable to shareholders, citing either RMB 219 million or RMB 221 million. The final figure should be based on the financial statements in the formal interim-results announcement filed with the Hong Kong Stock Exchange.

4.3 Ex-Dividend and Payment Arrangements for the Interim Dividend

The interim dividend is HKD 1.15 per share, with an ex-dividend date of September 30, 2026. The record date and arrangements for suspension of registration of share transfers are subject to the company’s announcement; market information indicates a payment date of October 23, 2026. The interim dividend for the same period in 2025 was HKD 0.35 per share. The actual payout ratio should be calculated based on the formal financial statements and share count.

4.4 Company Repurchased 108,900 Ordinary Shares on August 31, 2026

On August 31, 2026, Gushengtang repurchased 108,900 ordinary shares on the Stock Exchange of Hong Kong. The shares were intended to be held as treasury shares rather than cancelled. The repurchase price ranged from HKD 27.06 to HKD 27.44, with an average transaction price of approximately HKD 27.27. Total repurchase consideration was approximately HKD 2.9696 million, equivalent to approximately 0.0491% of issued shares excluding treasury shares before the repurchase. The amount was small relative to the company’s cash resources and market capitalization, so the short-term accretion to EPS is limited.

4.5 Share and Treasury-Share Position as of August 31, 2026

As of August 31, 2026, the company had approximately 221,965,451 issued shares excluding treasury shares, approximately 12,514,500 treasury shares, and approximately 234,371,051 total issued shares. Monthly repurchases in August totaled 108,900 shares. According to summarized repurchase data, the company had repurchased approximately 2.3934 million shares on the exchange since the relevant repurchase mandate, for an aggregate amount of approximately HKD 64.8759 million. Because some repurchased shares were held as treasury shares and some earlier shares were intended for cancellation, aggregate figures differ depending on statistical definitions and should be checked item by item against the HKEX monthly returns and next-day disclosure reports.

4.6 Disclosure of Monthly Return of Equity Issuer for the Month Ended August 31, 2026

On September 3, 2026, the company disclosed the monthly return of equity issuer for the month ended August 31, 2026, confirming that the 108,900 shares repurchased on August 31 were credited to treasury shares. There were no major records of new ordinary-share issuance during the month due to share options or other arrangements. The company confirmed compliance with the public-float requirements under the Hong Kong Listing Rules. The group’s USD 110 million, 2% annual-coupon convertible bonds due 2031 remained outstanding, with a conversion price of HKD 37.77 per share and a theoretical conversion into approximately 22,915,071 shares. These shares represent a potential source of dilution and were not newly issued during the month.

4.7 Ruiyuan Fund Reportedly Increased Its Gushengtang Holdings

Public market information indicates that Ruiyuan Fund Management Company Limited increased its Gushengtang holdings by approximately 120,000 shares on August 31, 2026, at approximately HKD 27.2892 per share, for a total amount of approximately HKD 3.2747 million. This information comes from third-party reporting of HKEX disclosure-of-interests data. The research notes did not directly obtain the corresponding original HKEX disclosure-of-interests document, so the ultimate change in ownership percentage, nature of the interest, and whether the holding was at the fund-product level cannot yet be confirmed. The increase was similar in amount to the company’s concurrent repurchase of approximately HKD 2.9696 million, but the single purchase represented a small percentage of total share capital and was insufficient on its own to constitute a material change in the shareholder structure.

4.8 Notice of Board Meeting to Consider Interim Results and Dividend

On August 18, 2026, the company announced that the board would meet on August 28, 2026 to consider the unaudited interim results for the six months ended June 30, 2026 and consider the declaration of an interim dividend. This was a procedural announcement before the results release, subsequently implemented through the interim-results and interim-dividend announcements on August 28, 2026.

4.9 No September 2026 Profit Warning or Earnings Forecast Identified

As of September 13, 2026, no profit warning, profit forecast, earnings downgrade, or delayed-results announcement issued by Gushengtang in September 2026 had been identified. The company’s most recent major results disclosure was the interim-results announcement on August 28, 2026, which showed year-on-year growth in both revenue and profit attributable to shareholders, with profit growth exceeding revenue growth. This finding only means that no relevant document was identified in HKEX announcements, etnet, or public market information; it does not constitute formal company guidance for full-year results.

4.10 No Major Regulatory, Disciplinary, or Compliance-Investigation Announcement Identified

As of September 13, 2026, no disciplinary action, regulatory censure, trading suspension, resumption, auditor-qualified opinion, or major compliance investigation announcement concerning Gushengtang had been identified from the HKEX, the Securities and Futures Commission of Hong Kong, or company announcements. Continued attention should be paid to the completion conditions for the Malaysian acquisition and to potential local requirements after overseas medical-institution M&A, including medical-practice licenses, company registration, medical-institution operations, and financial-consolidation compliance. The announcement did not disclose the specific conditions precedent, payment amount, historical revenue or profit of the target companies, or a detailed timetable for Malaysian regulatory approvals.

5. Share-Price Performance and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

As of September 11, 2026, 02273 closed at HKD 26.54, below MA5, MA10, and MA20, with RSI at approximately 45.64. The technical picture indicated weak consolidation rather than extreme oversold conditions. After the August 28 results catalyst, the share price retreated from approximately HKD 29.10 and recently traded mainly in the HKD 26–27 range. The September 11 close fell below the short-term high-volume trading zone of HKD 26.7–27.0, but volume was only approximately 600,000 shares, below the three-month average of approximately 970,000 shares, and did not indicate a high-volume sell-off. Initial resistance is around HKD 26.9–27.1 at the moving averages, followed by HKD 27.5–27.6. Support is around HKD 26.4–26.8 and HKD 25.9–26.2. Because the latest MACD value, complete top-10 shareholder concentration, and current-date net capital-flow data are unavailable, an overly definitive trend judgment is not appropriate.

5.3 Short-Term Outlook (Next Week, Scenario Analysis for Reference Only)

⚠️ Risk warning: The following content is a subjective scenario analysis based on the September 11, 2026 closing data and historical technical indicators. It does not constitute investment advice or a guarantee of future share-price performance.

1. Key Technical Levels

2. Scenarios for the Next Week (Subjective Weightings, Not Statistical Probabilities)

• Consolidation (relatively high subjective weighting, approximately six-tenths; a heuristic subjective weighting based on the current technical and liquidity backdrop, not a statistical probability): Price range approximately HKD 26.4–27.6. Trigger conditions include holding HKD 26.4–26.8, trading volume remaining within the recent normal range of approximately 400,000–1 million shares, no new strong catalyst or significant negative news, and no clear one-way move in the Hang Seng Index or healthcare-services sector. If this scenario holds, the share price may fluctuate around HKD 26.8–27.1, with HKD 27.0–27.6 remaining the main rebound resistance zone.
• Weak downside (medium subjective weighting, approximately three-tenths; a heuristic subjective weighting based on the current technical and liquidity backdrop, not a statistical probability): Price range approximately HKD 25.9–26.4. Trigger conditions include consecutive closes below HKD 26.4, downside volume materially exceeding the recent average, RSI continuing to fall below 40, or simultaneous weakness in the healthcare sector and Hang Seng Index. A break of the strong-support zone at HKD 25.9–26.2 could technically open room toward approximately HKD 25.0 and even the 52-week low of HKD 24.32.
• Stronger rebound (low subjective weighting, approximately one-tenth; a heuristic subjective weighting based on the current technical and liquidity backdrop, not a statistical probability): Price range approximately HKD 27.6–28.2. Trigger conditions include reclaiming HKD 27.1, further breaking HKD 27.5–27.6, daily volume materially exceeding the recent average, and continued increases in turnover value on up days, together with strengthening in the healthcare-services sector or broader Hong Kong market, or a new company catalyst. If HKD 27.6 is confirmed as broken, HKD 27.9–28.2 may be observed; without volume confirmation, a one-day spike may still represent only a range-bound rebound.

3. Capital and Liquidity Background

As of September 11, 2026, the turnover rate was approximately 0.26%, trading volume approximately 602,000–606,000 shares, and turnover value approximately HKD 16.15 million, below the three-month average trading volume of approximately 970,000 shares. Regarding shareholder information, Action Thrive Group Limited held approximately 14.43%, with a filing date of September 1, 2026, while Ruiyuan Fund Management Company Limited held approximately 7.20%, with a filing date of June 10, 2026. Their disclosed combined holdings totaled approximately 21.63%. Investing’s classification showed mutual funds and ETFs at approximately 17.01% and other institutional investors at approximately 29.21%, but this classification is not equivalent to a complete top-10 shareholder list from the Hong Kong Stock Exchange. Shareholder data may also be subject to quarterly or individual-disclosure lags, and actual holdings may have changed. Major-shareholder and fund-management-related participation can currently be confirmed, but complete top-10 shareholder concentration as of September 11, 2026 cannot. In practice, this means that the effective free float may be lower than nominal total share capital. When volume is low, relatively small fund flows may cause more pronounced price volatility, bid-ask spreads, and slippage; technical breakouts also require volume confirmation.

A volume-confirmation signal to monitor is that daily trading volume reaches more than 1 million shares for consecutive sessions, turnover value reaches approximately HKD 25–30 million or above, and the share price closes above HKD 27.5–27.6. This could be regarded as a more meaningful signal of capital participation or breakout confirmation. Conversely, if HKD 26.4 is broken with volume exceeding 1 million shares and the close near the intraday low, expanding selling pressure would warrant attention.

4. Points to Monitor (Observation Framework Only, Not Trading Instructions)

• Observe whether HKD 26.4–26.8 forms short-term support; if it fails, monitor the strong-support zone at HKD 25.9–26.2. This is an observation framework, not a trading instruction.
• Observe whether the HKD 27.0–27.6 resistance zone can be broken with volume confirmation. This is an observation framework, not a trading instruction.
• Observe whether volume can recover from approximately 600,000 shares to above 1 million shares, while turnover value rises simultaneously to above approximately HKD 25–30 million. This is an observation framework, not a trading instruction.
• Observe whether RSI can recover from around 45 to above 50 and whether MACD can be confirmed by the latest reliable data source as turning upward. This is an observation framework, not a trading instruction.

The above scenario analysis is based on the September 11, 2026 closing data and historical price and technical-indicator calculations. Short-term share prices may also be affected by news, liquidity, broader-market conditions, and other factors. Technical indicators are inherently lagging and limited. This does not guarantee future actual performance or constitute a buy or sell recommendation. Investors should independently assess the latest market information and bear their own investment risks.

6. Industry Structure and Competitor Analysis

6.1 Industry Status

China’s TCM medical-services industry comprises numerous institutions and remains regionally fragmented. Large public TCM hospitals have advantages in brand, specialists, and medical insurance, while private TCM clinics are mainly regional, small-scale, and individually operated. The industry relies heavily on renowned-doctor resources, patient reputation, and repeat-visit rates, and is difficult to standardize and replicate. Chain expansion, digitalization, and online-offline integration remain at a developing stage. Industry concentration is low, leaving room for M&A consolidation.

6.2 Competitive Landscape

• Core competitive factors include renowned doctors and specialist resources, physician revenue-sharing and incentive mechanisms, medical-insurance designation and payment channels, the quality and supply chain of Chinese medicinal materials, treatment results and patient reputation, store location, online booking and follow-up consultations, delivery capabilities, chronic disease management, membership systems, brand influence, and cross-regional M&A and operating capabilities.
• Large public TCM hospitals and TCM departments of general hospitals are important substitute competitors, with stronger tertiary-hospital brands, medical insurance and research resources, as well as more renowned doctors and capabilities in treating complex diseases.
• Compared with ophthalmology, dentistry, and other specialties with a higher degree of standardization, TCM services rely more heavily on physicians’ personal brands and individualized prescriptions. Large chains’ procurement, brand, and digital advantages cannot fully replace the non-standardizable nature of physician resources.
• Public industry data and brokerage research characterize the industry as “small, fragmented, and disorderly.” Some sources estimate Gushengtang’s share of the nationwide TCM medical market at below 1% and its share of the private TCM market at approximately 1%–2%. Market definitions differ among sources, and these figures should not be treated as audited data. The research notes also point out that different figures such as approximately 0.6%, 1.9%, or below 1% are not directly comparable.
• Gushengtang’s relative differentiation lies in its nationwide chain network, online-offline integration, convenience of visits, online booking and follow-up services, relatively flexible physician-cooperation mechanisms, membership system, and coverage of grassroots and chronic-disease management.

6.3 Major Competitors

Compared with regional TCM clinics, Gushengtang has a broader cross-regional store network, stronger online-offline integration, and greater capital-market financing capabilities. Compared with competitors such as Tong Ren Tang Healthcare and Zhang Zhongjing National Medical Hall that possess pharmaceutical or brand resources, its core model is more focused on asset-light chain TCM clinics, physician-resource networks, and an internet-hospital platform. Overall industry concentration remains low, but the difficulty of standardizing and replicating physician resources, medical-insurance and local regulatory requirements, M&A integration, and store-expansion costs are the main constraints on scaling.

7. Risk Factors

• Physician-resource and renowned-doctor dependence: The company’s TCM diagnosis and treatment depend heavily on physicians’ experience, professional reputation, and patient trust. Physician and materials costs accounted for approximately 80.2% of 2024 cost of sales. The loss of key physicians, higher revenue-sharing or incentive costs, or insufficient physician resources at new stores could affect customer traffic, revenue, and gross margin.
• Store-expansion and M&A-integration risk: The company uses parallel greenfield-development and M&A models and acquired or integrated several domestic and Singapore medical institutions in 2024. If patient traffic, physician staffing, or operating efficiency at new institutions falls short of expectations, integration costs could rise, profit margins could come under pressure, or operating impairment pressure could emerge.
• Uncertainty around the Malaysian acquisition: As of September 13, 2026, the proposed acquisition of three Malaysian TCM medical institutions had not been confirmed as completed. The announcement did not disclose the consideration, the target companies’ historical revenue or profit, or a detailed timetable for local regulatory approvals. The transaction may be delayed or fail to complete, and the contribution from overseas operations is uncertain.
• Medical-insurance receivables and working-capital risk: As of December 31, 2024, net trade receivables were RMB 269.4 million, and medical-insurance settlement periods ranged from 30 to 365 days from the transaction date. As offline institutions and medical-insurance business expand, receivables and working-capital usage may continue to increase, creating collection-cycle and impairment risks.
• Chinese medicinal-material and consumables cost risk: At the end of 2024, inventories of pharmaceuticals, consumables, and packaging materials were RMB 179.5 million. The company uses Chinese herbal slices, premium medicinal materials, and various physical-therapy consumables. Fluctuations in the variety, quality, origin, and market prices of premium medicinal materials could affect inventory value, procurement costs, and the gross margin of healthcare solutions.
• Industry competition and service-standardization risk: The company competes with large public TCM hospitals, TCM departments of general hospitals, and regional private TCM clinics. Public institutions have advantages in brand, specialists, medical insurance, research, and complex-disease treatment. Meanwhile, TCM prescriptions and treatment results are difficult to standardize, potentially limiting Gushengtang’s cross-regional replication and improvements in store utilization.
• Online customer-acquisition efficiency risk: Online healthcare-platform revenue declined 1.5% year on year in 2024, while third-party customer-acquisition costs within selling and distribution expenses increased 73.9% year on year to RMB 7.080 million. If online traffic costs continue to rise without corresponding improvements in bookings, follow-up visits, and conversion rates, the profit contribution of online operations may weaken.
• Equity and convertible-bond dilution risk: The company’s USD 110 million, 2% annual-coupon convertible bonds due 2031 remain outstanding, with a conversion price of HKD 37.77 per share and a theoretical conversion into approximately 22.915 million shares. If converted in the future, they could dilute existing shareholders’ ownership percentages and EPS.
• Hong Kong-market liquidity and valuation volatility risk: On September 11, 2026, trading volume was approximately 600,000 shares and the turnover rate approximately 0.26%, below the three-month average of approximately 970,000 shares. If the effective free float is lower than nominal total share capital, relatively small fund flows may amplify share-price volatility, bid-ask spreads, and slippage. The current P/E is also affected by TTM versus forecast earnings, the RMB/HKD exchange rate, and share-count definitions, so valuation judgments may change as data are updated.

8. Conclusion and Outlook

Gushengtang’s medium- to long-term growth foundation lies in the low industry concentration, the remaining consolidation potential in private TCM medical-services chains, and the company’s operating model combining offline institutions, physician resources, and an online platform. If new stores can continue to improve utilization, physician supply and repeat visits continue to grow, and M&A projects are integrated successfully, revenue expansion may continue to translate into earnings growth. The significantly faster profit growth than revenue growth in the first half of 2026 provides a temporary indication of improved operating efficiency.

However, revenue growth has slowed from the elevated level seen in 2024, making future growth more sensitive to the contribution of store expansion, M&A integration, overseas operations, and new businesses such as consumer healthcare. TCM services depend on individual renowned doctors’ brands and treatment capabilities, making standardized replication difficult. In addition, the high proportion of physician and materials costs and the long medical-insurance settlement cycle may constrain improvements in profit margins and cash flow. The Malaysian acquisition remains subject to contractual conditions precedent, and its consideration, target-company profitability, and regulatory-approval timetable have not been disclosed; its contribution cannot be assessed with confidence in the short term.

From a technical perspective, HKD 26.4–26.8 is the recent first support zone, while HKD 25.9–26.2 is the next important area to monitor. HKD 27.0–27.6 faces resistance from moving averages and the high-volume trading zone. Whether the subsequent trend improves will depend on whether the share price can reclaim approximately HKD 27.1 and break through HKD 27.5–27.6 with volume confirmation. This should be assessed together with subsequent financial reports, M&A progress, cash flow, and physician and store operating data.

Data Sources

• https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0521/2026052101308.pdf
• https://www.hkexnews.hk/listedco/listconews/sehk/2025/0429/2025042901075.pdf
• Gushengtang (02273) 2024 Full-Year Results: Revenue Continues to Grow Rapidly, Innovative Initiatives Deliver Significant Results | AI_新浪财经_新浪网
• Gushengtang: 2024 Annual Report - MBA智库文档
• First Shanghai—Gushengtang (2273.HK), TCM Chain Leader: Business Model and Industry Space Support Continued Growth—240906.pdf
• Investor Relations Center_Beijing Tong Ren Tang Healthcare Investment Co., Ltd.
• Wellsoon
• Home—Shengai TCM Clinic (Official Website)
• 2024 China TCM Physiotherapy Industry Enterprise Landscape Analysis: Industry Competition Is Dominated by SMEs and Highly Fragmented
• https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0331/2026033102676_c.pdf
• Listed Company Information Title Search
• Gushengtang: First-Half 2026 Net Profit Up 45.54%; Proposed Dividend of HKD 1.15 per Share _ 东方财富网
• CMB International Reaffirms 'Buy' on GUSHENGTANG with a HK$42 Target Price Following Robust First-Half Results - Tiger Brokers
• [MN

2026 年 4 月 2 日

CMB International Global Markets | Smart Investment | Company Update

Gushengtang](https://pdf.dfcfw.com/pdf/H3_AP202604021820971127_1.pdf?1775119962000.pdf=&utm_source=openai)

• [BOCOM International Research

Financial Model Update

Pharmaceuticals

April 2, 2026

Closing Price

Target Price

Potential Upside

HKD 2](https://pdf.dfcfw.com/pdf/H3_AP202604031821007978_1.pdf?1775213943000.pdf=&utm_source=openai)

• Guosen Securities—Gushengtang (02273.HK): Full-Year Results Grew Steadily; AI Business and Overseas Expansion Progressed Smoothly—260415.pdf
• Securities Research Report · Overseas Company Review · Other Healthcare (HS) | Gushengtang (02273.HK)
• 02273.HK Gushengtang | GUSHENGTANG | Company Information—Earnings Forecast Overview—etnet
• 02273.HK Gushengtang | GUSHENGTANG | Company Information—Earnings Forecast Overview—etnet
• Gushengtang (02273) P/E | Valuation | Fundamentals—Lixinger
• Gushengtang: 2025 Results Grew Against the Trend; Organic Growth, External Expansion, and New Businesses to Drive 2026; Maintain Buy—Industry Research Report
• [Gushengtang (02273) Announcements and Notices—[Other—Latest Business Development] Voluntary Announcement—Acquisition of 100% Equity Interest in Target Companies](https://www.cnfin.com/announ/detail/index.html?announ=hk&code=02273&dannoun=hkdetail&id=841200154808&utm_source=openai)
• Gushengtang (02273) Releases Interim Results: Profit Attributable to Shareholders of RMB 221 Million, Up 45.54%—智通财经
• Dividend Announcement—etnet
• [Gushengtang (02273) Next-Day Disclosure Report—[Share Repurchase] Next-Day Disclosure Report—新浪财经](https://finance.sina.com.cn/stock/aigc/hkgg/2026-08-31/doc-iniqfeam7941791.shtml?utm_source=openai)
• Gushengtang (02273) Repurchases—Lixinger
• https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0803/2026080303034.pdf
• Ruiyuan Fund Increased Its Gushengtang (02273) Holdings by 120,000 Shares at Approximately HKD 27.29 per Share—智通财经
• https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0818/2026081800992.pdf
• 02273—Stock Quotes for Gushengtang Holdings, HKEX:02273 Stock Price, Charting, News—Webull
• Gushengtang Holdings Ltd (2273) Historical Prices—Investing.com
• 2273 | Gushengtang Holdings Ltd Stock—Investing.com
• Gushengtang Holdings Ltd Technical Analysis (2273)
• GUSHENGTANG (02273.HK)—Detailed Quote

This report was automatically retrieved, compiled, and generated by AI based on publicly available information. Information is current as of the Hong Kong market close on September 11, 2026; September 13, 2026 was a Sunday, and there was no new Hong Kong market closing data. Reporting currency: Hong Kong dollars (HKD). Information may be subject to timing differences; specific data should be based on the company’s formal announcements and authoritative data terminals. This report is for information organization and research reference only and does not constitute investment advice. Investors should make independent judgments and bear their own investment risks.